Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Attacking cancer at its foundation.

× No keyword cloud information.

59 in total

Review 1. Oncogenic kinase signalling.

Authors: P Blume-Jensen; T Hunter
Journal: Nature Date: 2001-05-17 Impact factor: 49.962

Review 2. Protein kinases--the major drug targets of the twenty-first century?

Authors: Philip Cohen
Journal: Nat Rev Drug Discov Date: 2002-04 Impact factor: 84.694

3. Selecting the right patient for tumor therapy.

Authors: Carlos L Arteaga
Journal: Nat Med Date: 2004-06 Impact factor: 53.440

4. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Authors: M C Heinrich; D J Griffith; B J Druker; C L Wait; K A Ott; A J Zigler
Journal: Blood Date: 2000-08-01 Impact factor: 22.113

Review 5. Gefitinib--a novel targeted approach to treating cancer.

Authors: Roy S Herbst; Masahiro Fukuoka; José Baselga
Journal: Nat Rev Cancer Date: 2004-12 Impact factor: 60.716

6. Development of solid-phase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine protein kinase activity.

Authors: K Farley; H Mett; E McGlynn; B Murray; N B Lydon
Journal: Anal Biochem Date: 1992-05-15 Impact factor: 3.365

7. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.

Authors: Magnus K Magnusson; Kristin E Meade; Ryotaro Nakamura; John Barrett; Cynthia E Dunbar
Journal: Blood Date: 2002-08-01 Impact factor: 22.113

8. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors: Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal: JAMA Date: 2003-10-22 Impact factor: 56.272

9. Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors.

Authors: E McGlynn; M Becker; H Mett; S Reutener; R Cozens; N B Lydon
Journal: Eur J Biochem Date: 1992-07-01

10. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Authors: Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245

8 in total

Review 1. The molecular pathology of cancer.

Authors: Timothy J R Harris; Frank McCormick
Journal: Nat Rev Clin Oncol Date: 2010-03-30 Impact factor: 66.675

2. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.

Authors: Yen-Lin Lin; Benoît Roux
Journal: J Am Chem Soc Date: 2013-09-20 Impact factor: 15.419

3. Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.

Authors: Elizabeth A Larocque; N Naganna; Clement Opoku-Temeng; Alyssa M Lambrecht; Herman O Sintim
Journal: ChemMedChem Date: 2018-05-22 Impact factor: 3.466

Attacking cancer at its foundation.